Wereport a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy. A 52-year-old womansuffered from chronic active hepatitis type C and was treated with a total of 456xlO6 units of IFN-oc for 23 weeks. During the 12th week of treatment she showed transient thyrotoxicosis. One week after the termination of IFN therapy, TSH-receptor antibodies became positive and subsequently she showed Graves' hyperthyroidism. This case showedsequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of Graves' hyperthyroidism during IFN therapy. The course of this case may be useful in the understanding of the pathogenesis of autoimmune hyperthyroidism. (Internal Medicine 34: 58-60, 1995) 
Introduction
Graves' hyperthyroidism is thought to be an autoimmune disease and autoantibodies to TSH-receptor (TBII and TSAb) play a causative role in the disease (1) . Interferon (IFN) has been shown to be effective, and is widely used for the treatment of viral hepatitis and cancers. However, long-term IFN treatment has been knownto induce a variety ofautoantibodies, and in certain cases autoimmunedisorders, especially thyroid dysfunction (2) (3) (4) (5) (6) (7) . Wereport here a case of Graves' hyperthyroidism following transient thyrotoxicosis and the appearance of TSH-receptor autoantibodies during long-term IFN therapy for viral hepatitis type C.
Materials and Methods
Laboratory tests for thyroid function were assayed as described in a previous report (8) . Serum T3, T4, free T3, free T4 and TSHconcentrations were measured by radioimmunoassay or immunoradiometric assay using a commercially available kit. Antibodies to microsomal fraction (MCHA)and to thyroglobulin (TGHA)were measured by the tanned red cell hemagglutination technique. Antibodies to thyroid peroxydase (TPOAb) and to thyroglobulin (TgAb) were measured by radioimmunoassay. Net thyroidal 99mTcuptake was measured 30 min after an iv injection of 2 mCi of 99mTc-pertechnetate (normal range; 0.5-4.0%).
TSH-binding inhibitor immunoglobulin (TBII) activity was measured by radioreceptor assay, and thyroid-stimulating antibody (TSAb) activity was measured by Kasagi's method, using porcine thyroid cells (9) . The normal values of TBII and TSAbactivities are less than 10%and 140%, respectively.
Case Report
The subject of our study was a 52-year-old Japanese woman who was diagnosed with chronic hepatitis type C in April 1992. She had a history ofectopic pregnancy twice at the age of25 and 30 and received blood transfusions. (TBII 20 .6% and TSAb 367%). In July, she complained of palpitation and general fatigue and was admitted to our hospital. Physical examination revealed finger tremor, eye lid edema, and a soft thyroid gland with diffuse enlargement and a nodule. Thyroid function tests revealed the presence of hyperthyroidism ( Table 1 ). The thyroid radioactive 99mTc uptake was 2.3%. The patient was treated with propranolol and is now being followed up. The patient' s clinical course is shown in Fig.   1 .
Discussion
Graves' hyperthyroidism occurred in the present patient following transient thyrotoxicosis and the appearance of thyroid autoantibodies during IFN treatment. A diagnosis of Graves ' hyperthyroidism was made as the patient showed 1) clinical signs with diffuse goiter, 2) elevated levels of thyroid hormones with undetectable levels ofTSH, and 3) the presence of antibodies to TSH-receptors (TBII and TSAb). The normal radioactive 99mTcuptake ruled out destructive thyrotoxicosis. Recently, thyroid dysfunction, either hyperthyroidism or hypothyroidism, has been reported in a few patients during IFN therapy for viral hepatitis and cancers (2-7). Some reports claim that patients who had anti-thyroid antibodies before IFN treatment tended to show thyroid dysfunction after IFN therapy.
In the present study, the patient had no antibodies to thyroid proteins including TPOAb, TgAb and TSAb, nor any clinical thyroid dysfunction. The mechanism by which IFN-a induces thyroid dysfunction remains unclear, but the autoimmunemechanismis thought to play an important role. IFN-a enhances the surface expression of MHCclass I antigens (10), which activate cytotoxic T cell function. IFN-a also induces MHCclass II antigens on thyroid cells in patients with autoimmune thyroid diseases (1 1 , 12). Theaberrant expression of MHC antigens on the cell surface, in association with cellular antigens, maybe sufficient to interrupt the tolerance and induce autoantibody production (13) . Cytokines (TNFa, IL-1B) that are induced by IFN-a (14) may directly or indirectly disturb the thyroid function by their immunomodulatory effects. The pathogenesis of Graves' hyperthyroidism remains unknown, but it thought to be causally related to autoimmunity. The majority of patients have thyroid-stimulating antibody (TSAb). In some cases, transient thyrotoxicosis (such as destructive thyroiditis) is followed by Graves ' hyperthyroidism (15) (16) (17) . In such cases, destruction of thyroid tissues and release of autoantigens may disturb immunotolerance and the subsequent production of TSAb may result in hyperthyroidism.
In the present case, the appearance of TPOAband TgAbat the time of destructive thyrotoxicosis, which was followed by the appearance ofTSAb and hyperthyroidism, seems to be compatible with this hypothesis. This case was analyzed in detail and sequentially, from transient thyrotoxicosis to the appearance of thyroid autoantibodies and then to hyperthyroid Graves ' disease, which is suggestive of the pathogenesis of autoimmune hyperthyroidism.
